ToolsThe story, in brief
Anthropic launches its own drug discovery programs to tackle diseases Big Pharma considers unprofitable
Anthropic just became a drug company. Not a partner—a builder. Neglected diseases that Big Pharma won't touch.
The KeyNews take
Why it matters
Anthropic is expanding beyond AI infrastructure into vertical application (drug discovery), signaling how AI labs are capturing end-to-end value chains and competing in adjacent industries. This represents a strategic shift from model-as-a-service to applied outcomes-driven deployment.
The key facts
5 to knowAnthropic launches proprietary drug discovery program
Focus: neglected diseases Big Pharma deems unprofitable
Novartis CEO estimate: AI could reduce development timeline from 12 years to 7-8 years
Novartis CEO estimate: AI could increase success rate from 8% to 16%
Published July 4, 2026
Go to the source
The Decoderthe-decoder.com
Publisher excerpt: Anthropic is launching its own drug development program for neglected diseases that the pharmaceutical industry considers unprofitable. Novartis CEO Vas Narasimhan thinks AI could cut development time from twelve years to seven or eight and double the success rate from 8 to 16 percent.